1. Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia.
- Author
-
Ritter, M., Kattmann, D., Teichler, S., Hartmann, O., Samuelsson, M. K. R., Burchert, A., Bach, J.-P., Kim, T. D., Berwanger, B., Thiede, C., Jäger, R., Ehninger, G., Schäfer, H., Ueki, N., Hayman, M. J., Eilers, M., and Neubauer, A.
- Subjects
TRETINOIN ,ACUTE myeloid leukemia ,CYTOGENETICS ,ONCOGENES ,HISTONE deacetylase ,VALPROIC acid ,BONE marrow - Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease with multiple different cytogenetic and molecular aberrations contributing to leukemic transformation. We compared gene expression profiles of 4608 genes using cDNA-arrays from 20 AML patients (nine with −7/del7q and 11 with normal karyotype) with 23 CD34+ preparations from healthy bone marrow donors. SKI, a nuclear oncogene, was highly up regulated. In a second set of 183 AML patients analyzed with real-time PCR, the highest expression level of SKI in AML with −7/del7q could be confirmed. As previously described, Ski associates with the retinoic acid receptor (RAR) complex and can repress transcription. We wanted to investigate the interference of Ski with RARα signaling in AML. Ski was co-immunoprecipitated and colocalized with RARα. We also found that overexpression of wild-type Ski inhibited the prodifferentiating effects of retinoic acid in U937 leukemia cells. Mutant Ski, lacking the N-CoR binding, was no more capable of repressing RARα signaling. The inhibition by wild-type Ski could partially be reverted by the histone deacetylase blocking agent valproic acid. In conclusion, Ski seems to be involved in the blocking of differentiation in AML via inhibition of RARα signaling.Leukemia (2006) 20, 437–443. doi:10.1038/sj.leu.2404093; published online 19 January 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF